Stocks · News reference
CareDx Announces New KOAR Data at ASN Kidney Week 2026
CareDx released new data from the KOAR study demonstrating that elevated AlloSure Kidney levels are associated with a nearly 3-fold higher risk of adverse graft outcomes in patients with borderline rejection or T-cell mediated rejection (TCMR).
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Canaccord Genuity Maintains Buy on CareDx, Raises Price Target to $80
Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up
Cathie Wood's ARK dumps $18M of Twist Bioscience while buying Recursion, Veracyte and Intellia, extending its CRISPR bet to 50 sessions.